Can These Former Biotech Growth Stocks Regain Their Form?

All that being said, biotech stocks in the middle of an important commercial launch or long-winded clinical trial can be powerful growth vehicles. Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. While there's no guarantee that either of these names will regain its prior form as a top growth stock, these two biotech companies do sport the type of key assets to spark a comeback.